NDAORALTABLET
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
IRA Negotiated
ZITUVIMET (sitagliptin and metformin hydrochloride) by Aurobindo Pharma is dipeptidyl peptidase 4 inhibitors [moa]. First approved in 2023.
Drug data last refreshed 4h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZITUVIMET is a fixed-dose combination oral tablet containing sitagliptin (a DPP-4 inhibitor) and metformin hydrochloride, approved by the FDA on November 3, 2023. It is indicated for type 2 diabetes management by enhancing insulin secretion and improving glucose control. The combination leverages complementary mechanisms: sitagliptin increases incretin levels while metformin reduces hepatic glucose production.
Growth
Early-stage growth product with significant IRA price negotiation impact; brand team will focus on payer access and managed market positioning during critical launch phase.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
Started Jun 2024
34 enrolled
Healthy Subjects
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
Started Apr 2024
34 enrolled
Healthy Subjects
Career Relevance
ZITUVIMET offers early-stage product opportunities within a growth-phase launch environment, particularly in market access, payer negotiation, and field sales as the brand builds formulary presence. Career trajectory will be shaped by successful market penetration in a competitive diabetes space and navigating significant IRA price compression.
Worked on ZITUVIMET at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.